| Quantity | 1 mg, 5 mg, 10 mg | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 1 mg | 1 mg, 5 mg, 10 mg, 25 mg | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor | [Leu5]-Enkephalin is a pentapeptide with morphine like properties. [Leu5]-Enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors | Ceramide 1-phosphate is a bioactive lipid and one of the key components of sphingolipids. Ceramide 1-phosphate playing diverse roles in cellular behaviors such as cell differentiation, migration, proliferation and death[1] | DAMGO is a µ-opioid receptor (µ-OPR ) selective agonist with a Kd of 3.46 nM for native µ-OPR[1] | Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake[1]... Read More |